ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Virtual Course 2020

November 6, 13, & 20, 2020  
Virtual
Registration open for on-demand viewing

ISSWSH Annual Meeting 2021

March 5-7, 2021  
Virtual
Registration open for on-demand viewing

ISSWSH Fall Course 2021

October 7-10, 2021   174 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

ISSWSH Annual Meeting 2022

March 3-6, 2022   324 days left
Renaissance Dallas Hotel - Dallas, TX
Visit the Meeting Website

Latest Tweets

Up to 20% of people with vulvodynia have irritable bowel syndrome (IBS). It's important to look for IBS when evalua… https://t.co/4njt88jkcD ISSWSH
Registration is open for the Essentials of Female Sexual Health Virtual Course on June 4, 2021 - presented by NPWH… https://t.co/wKkxre3Lsd ISSWSH
Did you know April is Stress Awareness Month? Stress can be a factor in sexual dysfunction. Sensate focus is a sex… https://t.co/Sh2FxvF4zd ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram